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Surveillance of human immunodeficiency virus type 1 transmitted drug resistance (TDR) was conducted
among pregnant women in South Africa over a 5-year period after the initiation of a large national
antiretroviral treatment program. Analysis of TDR data from 9 surveys conducted between 2005 and 2009 in
2 provinces of South Africa suggests that while TDR remains low (<5%) in Gauteng Province, it may be
increasing in KwaZulu-Natal, with the most recent survey showing moderate (5%–15%) levels of resistance to
the nonnucleoside reverse transcriptase inhibitor drug class.
South Africa has adopted a public health approach to
antiretroviral (ART) delivery using standardized
treatment options and management protocols. By the
end of 2009, an estimated 970 000 South Africans
infected with human immunodeficiency virus (HIV)
type 1 were accessing ART through the public health-
care system [1]. The first-line regimen at this time was
stavudine, lamivudine, and efavirenz or nevirapine,
with ritonavir-boosted lopinavir being used for treat-
ment of infants and as a second-line regimen in adults.
The annual antenatal survey (ANSUR), conducted by
the National Department of Health, is an anonymous,
unlinked cross-sectional survey that estimates HIV
prevalence using blood specimens taken from pregnant
women aged 15–49 years attending 1 of the 1457 public
health sector antenatal clinics across all 9 provinces in
South Africa. Between 2005 and 2009, the number
of pregnant women participating in these surveys
increased from 16 510 to 32 861 [2, 3]. The majority
of women were from the Gauteng (GP) (21.9%) and
KwaZulu-Natal (KZN) (20.5%) provinces, with roughly
half being between ages 15 and 24 years. In 2009, the
national HIV prevalence estimate was 29.4% with 29.8%
in GP and 39.5% in KZN.
Emergence of HIV drug-resistant strains is an in-
evitable consequence of ART, which has been potentially
exacerbated by rapid up-scaling of population-based
treatment regimens. The World Health Organization
(WHO) recommends surveillance for transmitted drug
resistance (TDR) in countries where ART has been
available for .3 years among individuals likely to be
recently infected, such as women aged,25 years in their
first pregnancy [4]. This minimum-resource method
analyzes #47 specimens from individuals consecutively
identified as HIV-infected to categorize TDR as low
(,5%), moderate (5%–15%), or high (.15%) [5].
Levels of TDR have remained low despite extensive
HIV drug resistance (HIVDR) being documented
among patients failing first-line therapies in resource-
limited countries, [6].
An earlier survey conducted in GP between 2002
and 2004 [7] showed low levels of TDR, which was
not unexpected given that the national ART program
began in April 2004. In this study, we performed
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a retrospective analysis of HIVDR using ANSUR specimens
from GP and KZN, obtained between 2005 and 2009, and
spanning the time during which the national ART program
expanded significantly.
METHODS
ANSUR Specimens
All participants were from GP or KZN and were part of the
2005–2009 ANSUR. Anonymized demographic data were
recorded on a standardized collection form. All individuals
in this analysis met the inclusion criteria as defined by the
WHO guidelines for classification of TDR (primigravid fe-
male, aged ,25 years) [4]. Data from 9 surveys were available
for analysis. (The KZN-2006 survey was not included.) Ethical
approval for HIVDR testing was obtained from the University
of the Witwatersrand Human Research Ethics Committee.
Specimen Collection and HIV Testing
Serum specimens were collected during routine antenatal care
and tested for HIV infection by enzyme-linked immunosorbent
assay (Abbott AxSYM System for HIV-1 and HIV-2, Abbott
Laboratories). HIV-1 positive specimens were further charac-
terized using the Calypte Aware BED EIA HIV-1 Incidence Test
(Calypte Biomedical Corporation), which detects recent in-
fection based on HIV-specific antibody affinity [8]. The cutoff
for this assay was normalized optical density of #0.8 [9]. The
v2 test was used for statistical analysis of BED Incidence Test
data in the resistance study sample relative to the entire survey.
Multivariate logistic regression analysis was done using data
from all women aged #30 years in 8 surveys to explore the
factors associated with recent infection. Variables available in
the dataset included age, gravidity, year of survey, and prov-
ince. Results were reported with odds ratios (ORs), 95% con-
fidence intervals (CIs), and P values.
Genotyping
Resistance genotyping was performed using remnant serum
specimens stored at 270C following serological testing.
Sequencing of the pol gene was done using an in-house assay
certified by the Virology Quality Assessment program. In brief,
a nested polymerase chain reaction (PCR) was performed using
previously defined methods to generate a 1.7-kb amplicon
spanning both the protease and reverse transcriptase genes [7].
In cases where there was no amplification of the pol gene, the
protease and reverse transcriptase regions were amplified
separately [10, 11]. Genotypic resistance was defined as the
presence of resistance mutations using the Stanford Calibrated
Population Resistance algorithm, version 4.1 beta [12, 13].
Specimen subtype was assigned using the same algorithm. Se-
quences were ordered according to date of collection and prev-
alence classification assigned according to the recommended
WHO method [5]. If no resistance was found within the first 34
specimens, prevalence was classified as low (,5%). If resistance
was detected, then 47 sequences were evaluated. If the number
of sequences with relevant resistance mutations was between
2 and 8, the prevalence of TDR was classified as moderate
(5%–15%).
RESULTS
Demographic Data From Amplified Specimens
Specimens were selected from 9 surveys conducted between
2005 and 2009 in GP and KZN (Table 1). A total of 1006
specimens were subjected to resistance testing, from which
354 analyzable sequences were obtained (35%). All specimens
were subtype C, except for 1 subtype B (KZN-2008), 1 subtype A
(GP-2009) and 1 subtype D (KZN-2009). In all surveys, the
median age of women was between 19 and 21 years.
Classification of Threshold Survey Sequence Data
Five surveys were conducted in GP utilizing 294 specimens,
from which 196 sequences were obtained (67%). The PCR
amplification rate ranged from 76% to 93% in 4 surveys but
was lower in 2007 at 46%. In all surveys, the levels of TDR
for the nucleoside reverse transcriptase inhibitor (NRTI) and
nonnucleoside reverse transcriptase inhibitor (NNRTI) drug
classes were ,5% [5]. In 2005, the protease gene was not
analyzed; thus, a classification could not be made. In 2007,
1 specimen had the protease inhibitor (PI) mutation M46I.
An additional sequence had 185V, which was not considered
a surveillance drug resistance mutation (SDRM) at the time
of this survey (GP-2007) and therefore was not included in
the final analysis. Overall, levels of TDR for the PI class of
drugs for 2006–2009 in GP were classified as low (,5%).
Four surveys were conducted in KZN. A total of 712 speci-
mens were analyzed, from which 158 sequences were obtained
(22%). PCR amplification rates were too low in 2005 (13%) and
2008 (14%) to allow us to reach the required number of
sequences (n 5 47), and TDR classification was not possible
in these years. In 2007, 67% of specimens were amplified; no
resistance was detected in sequences from the first 34 speci-
mens, allowing us to categorize transmitted resistance levels
as low (,5%) according to the WHO method [5]. In the 2009
survey however, the presence of NNRTI mutations in 3 se-
quences resulted in a classification of moderate levels of
TDR (5%–15%) for the NNRTI class of drugs, whereas the
levels were low (,5%) for the NRTI and PI drug classes. In-
terestingly, 2 sequences with NRTI mutations and 3 sequences
with NNRTI mutations were identified in the preceding year.
However, a threshold could not be calculated for the 2008
survey, because numbers of sequences obtained were in-
sufficient to classify TDR based on the WHO method.
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Table 1. Transmitted HIV Drug Resistance Threshold Surveys Performed in Gauteng and KwaZulu-Natal Provinces, 2005–2009
Province Year
No. of
Specimens
Tested
No. of
Sequences
Analyzed
Amplification
Rate
Median Age
(Range), y
BED ‘‘Recent’’ Infections
HIV
Subtype
No. With
Mutations
Mutational Patterns
Threshold LevelEntire ANSUR
Resistance
Substudy P Value PI NRTI NNRTI
Gauteng
Province
2005 51 34 76% 21 (18–22) 100/1006 (11%) 7/34 (21%) .080 C 0 ,5% NRTI, NNRTI
2006 40 34 93% 20 (18–21) 265/1923 (14%) 0/34 (0%) C 0 ,5% all drug classes
2007 133 47 46% 20 (18–21) 572/2184 (26%) 17/47 (36%) .125 C 1 M46I M184I ,5% all drug classes
2008 43 34 81% 20 (18–21) 264/2251 (12%) 9/34 (27%) .009 C 0 ,5% all drug classes
2009 58 47 81% 19 (18–21) 245/2125 (12%) 10/47 (21%) .040 C (1A) 1 M184V Y188L ,5% all drug classes
KwaZulu-Natal
Province
2005 287 40 14% 21 (18–24) 263/1359 (19%) 7/40 (18%) .716 C 1 K101E Y181C ND
2007 61 34 67% 19 (18–22) 352/2715 (13%) 7/35 (20%) .220 C 0 ,5% all drug classes
M46I
M184V K103N
2008 284 37 13% 20 (18–24) 339/2676 (13%) 10/37 (27%) .144 C (1B) 5 K219R ND
K103N
K103N
K103N
2009 80 47 71% 19 (18–21) 506/2692 (19%) 15/48 (31%) .029 C (1D) 3 V106M ,5% PI, NRTI5-15%
NNRTI
K101P K103N
Bold text indicates significant P values.
Abbreviations: ANSUR, annual antenatal survey, South Africa; BED, BED EIA HIV-1 Incidence Test; HIV, human immunodeficiency virus; ND, not determined due to insufficient No. of available specimens; NNRTI,
nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
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Mutational Patterns
A total of 11 of the 354 sequences (3%) were found to harbor
resistance mutations (Table 1). The most common mutation
in reverse transcriptase was K103N, which was present in 5
sequences, followed by M184V in 3 sequences. One sequence
contained the SDRM K219R. For protease, 2 sequences had
M46I [13].
Use of Surrogate Markers to Assess Recent Infection
We further investigated whether specimens selected in the
resistance survey were enriched for recent infections. In 7 of
9 surveys, the proportion of recently infected women was
higher in the selected group relative to the entire survey
population, although it was only significant in 3 of the later
surveys because of small numbers (Table 1).
In order to determine whether the demographic criteria
used for inclusion into TDR surveys were also supported by
a classification of recent infection, a multivariate analysis was
performed assessing data from all women #30 years of age
participating in 8 of the 9 surveys. (GP-2005 was not included
due to missing demographic data.) A total of 12 397 women
were included in this analysis. Controlling for province, age,
gravidity, and year was independently associated with being
classified as recent infection by the BED Incidence Test. With
each increasing year of age, women were 9% less likely to be
classified as having a recent infection (OR, 0.91 [95% CI, .90–
.92]; P 5 .0000). Similarly, women were 12% less likely to be
classified as recent infection with each additional pregnancy
(OR, 0.88 [95% CI, .82–.94]; P 5 .0000). There was also an
association between recent infection and year of survey in
that women were 6% less likely to be classified as recent in-
fection for each year between 2005 and 2009 (OR, 0.94 [95%
CI, .91–.97]; P 5 .002).
DISCUSSION
We performed surveillance of TDR following the WHO-
suggested method, using specimens from the ANSURs con-
ducted by the South African National Department of Health.
This study used specimens collected between 2005 and 2009
and focused on 2 provinces, both with high HIV prevalence
estimates [3]. Our results indicated that the levels of TDR
were ,5% for all drug classes during this period in GP. In
KZN, levels were low in 2007 for all drug classes; they ap-
peared to be increasing in 2009 for NNRTIs, as the KZN-2009
survey was classified as having 5%–15% transmitted NNRTI
resistance.
This report is an update of an earlier publication reporting
low levels of TDR in ANSURs performed in GP in 2002 and
2004 [7]. Since this previous report, the national treatment
program has initiated ART in nearly 1 million HIV-infected
individuals [3]. Single-dose nevirapine, to prevent mother-to-
child transmission, was also in use during the time of these
surveys. Our results suggest that the levels of TDR in GP re-
mained unchanged at ,5% until 2009, as all surveys from this
province were classified as low for all 3 drug classes. However
in KZN, there was an indication that TDR may be increasing
for the NNRTI drug class, although only 2 of the 4 surveys were
evaluable. The 2007 survey showed levels of ,5%, while the
2009 survey showed levels of 5%–15% for the NNRTI drug
class. While insufficient sequences precluded analysis for TDR
in 2008, the presence of 5 sequences with mutations supports
the notion that resistance may have been increasing before
2009. It will be important to verify this finding by performing
follow-up surveys in 2010 in KZN, perhaps including addi-
tional sites.
One of the limitations of the study was the low frequency of
PCR amplification of specimens, particularly those from KZN,
which compromised the assessment of the 2005 and 2008
surveys. This is probably because these remnant serum speci-
mens were not adequately stored for optimal preservation of
viral RNA needed for resistance testing. Although unlikely
to compromise the interpretation of the data, the low ampli-
fication rate meant that high volumes of specimens had to be
tested. Despite this, there were insufficient sequences available
to perform TDR surveys in both 2005 and 2008. Since the
amplification rate was considerably lower in KZN than GP,
this suggests that logistical issues in specimen collection and
handling in KZN (confounded by the need to transport the
specimens to the drug resistance testing lab in GP) should be
examined particularly in light of the possibility that additional
surveys may need to be conducted in this province.
K103N and M184V were the most common mutations
detected. These mutations are associated with TDR and are
commonly found in patients failing first-line therapies in South
Africa [14–17]. K103N and M184V occur rarely in untreated
individuals [13] and are selected for by nevirapine/efavirenz
and lamivudine, respectively, causing high-level resistance to
these drugs. Thus, these women were either exposed to anti-
retroviral drugs or infected with a resistant strain. It is also
possible that the K103N mutation arose due to single-dose
nevirapine exposure despite no record of prior pregnancy.
K219R is listed as an SDRM for the purposes of transmitted
resistance, although the effect on NRTI susceptibility is un-
known. The M46I mutation found in 2 individuals is a PI
resistance–associated mutation that occurs at very low frequency
(,0.2%) among drug-naive persons. M46I can be poly-
morphic; its presence may not signify TDR, especially because
PI-based regimens are reserved for second-line treatment, and
other PI-associated mutations were not observed in this specimen.
While the ANSUR has been useful as a minimum resource
method for examination of TDR in resource-limited settings,
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the issue of whether demographic criteria are reliable surrogate
markers of recent infections remains open to discussion. We
found that specimens selected for these surveys were enriched
for individuals with recent infections as defined by BED EIA
HIV-1 Incidence Testing, although results were statistically
significant in only 3 surveys (probably due to the small sample
sizes). However, a multivariate analysis involving .12 000
women showed that young age and first gravidity were sig-
nificantly associated with a classification of recent infection.
Despite the recommendation that the predictive value of this
assay is too low to classify recent infection on an individual
basis [18], our initial assessment is that the BED Incidence
Test may be an additional useful measure to include when
developing inclusion and exclusion criteria for population-
based surveys of TDR.
TDR in resource-limited countries, such as South Africa, is
not unexpected. Increased levels have been detected over the
years in Europe and the United States [19, 20] and more recently
in Uganda, where ART programs have been in operation for
a longer time [21]. Because South Africa’s national ART
program began in 2004, it is not unexpected that earlier sur-
veys showed low rates of TDR. However, this report suggests
that increasing levels of transmitted NNRTI-resistant virus may
be occurring in KZN. This report must be treated with caution,
and ongoing vigilance is required. TDR surveillance should be
repeated in KZN and results confirmed. A systematic and
standardized assessment of factors occurring within the ART
delivery program, which may favor the selection of drug-
resistant virus in populations receiving care and its subsequent
transmission to newly infected individuals, needs to be im-
plemented.
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